The number of those events was small, it was not a hard outcome trial, but they were distributed quite favourably to semaglutide versus placebo
What has been shown in humans is the outcome rather than the mechanism
Semaglutide example (maintenance dose): Brand-name Wegovy: ~$1,350/month = ~$16,200/year Compounded (503B): ~$300/month average = ~$3,600/year Annual savings: approximately $12,600 Percentage savings: approximately 78% Tirzepatide example (maintenance dose): Brand-name Zepbound: ~$1,060/month = ~$12,720/year Compounded (503B): ~$375/month average = ~$4,500/year Annual savings: approximately $8,220 Percentage savings: approximately 65% Over a multi-year treatment course - and GLP-1 treatment is typically long-term - these savings compound dramatically
We examined the events involved in LD contact using a living cell station
Curr Ther res, Clin exp 1982;32(11):116-127